Major depressive disorder is one of the most common mental disorders. The etiology of this disorder remains largely unknown. It is likely to involve a complex interplay of multiple genes, developmental mechanisms and environmental factors.
1,2 Expression profiling using microarrays makes it possible to develop an overall view of the complex interplay of molecular and physiological pathways that may be involved in a disorder and thereby identify candidate mechanisms for the disorder. Microarrays have been applied to examine the molecular basis of schizophrenia, 3 -10 bipolar disorder 10, 11 and alcohol use disorders. 12 Several brain regions, including the prefrontal and temporal cortexes as well as limbic structures, have been implicated in major depressive disorder. [13] [14] [15] This study examined the expression levels of approximately 12 000 genes to identify candidate mechanisms associated with major depressive disorder in the temporal cortex (middle temporal gyrus). The temporal cortex was examined because it has been implicated in regulation of emotional states, 16, 17 and abnormalities in the temporal cortex have been reported in major depressive disorder in a number of studies. [17] [18] [19] [20] [21] For example, functional magnetic resonance imaging (fMRI) using a paradigm of evoking effect with picture-caption pairs demonstrated increased response in the middle temporal gyrus in patients with treatment-resistant depression. 20 This increased activity in the middle temporal gyrus with processing of negative picture-caption pairs is consistent with findings showing activation of this region during the processing of negative emotional scripts. 16 Furthermore, fMRI using an emotional activation paradigm showed that transient sadness produced significant activation in the middle temporal cortex in both depressed and normal subjects. 17 In addition to fMRI findings, low-resolution electromagnetic tomography revealed decreased activity in the right middle temporal gyrus in medication-free chronically depressed females. 21 Furthermore, single photon emission computed tomography (SPECT) revealed bilaterally decreased cerebral blood flow in the temporal cortex of patients with major depressive disorder. 18 
Materials and methods
Postmortem tissue (The Stanley Consortium 22 ) was derived from the middle temporal gyrus corresponding to Brodmann's area 21 (BA21) of 12 patients with major depressive disorder (DSM-IV) and 14 controls closely matched in age, gender, postmortem interval delay (PMI), brain pH, as well as 3 0 to 5 0 ratio for GAPDH and percentage of genes on each microarray called present, both determined from Affymetrix chip hybridization analysis (Table 1) . Control #24 was African American. All other subjects were Caucasians. Four patients with major depressive disorder (cases 7, 13, 34, 51) and two controls (cases 53, 55) had a history of substance abuse. Seven out of 12 patients with major depressive disorder were treated with CNS drugs (antidepressant or anxiolytic drugs; none were treated with neuroleptics) at time near to death. Two patients (cases 9 and 18) were untreated for more than 5 years. Another patient was off medication more than 2 weeks (case 33) and two other cases (34 and 49) had probably never been treated. Five patients with major depressive disorder died of suicide and seven other patients died due to other causes. Additional follow-up analyses of medication-free cases (n ¼ 5) or suicide-free cases (n ¼ 7) demonstrated that the vast majority of changes identified in the entire major depressive group were also present in the subgroups of medication-free and suicide-free patients. Thus, the majority of these changes were unlikely due to CNS drugs or suicide. None of the patients with major depressive disorder displayed psychotic features or had a diagnosis of bipolar disorder. One patient (case 35) had a first degree relative with bipolar disorder. Another patient (case 9) had a first degree relative with unspecified 'mental problems'. Seven patients had first (cases 34, 33, 49, 51, 37, 17) or second-(case 5) degree relatives with depression. No information about relatives was available in two cases (cases 7 and 20) . No relatives with mental problems were identified in case 18. Note that information on family history was based only on questions asked by the pathologist, or information available in psychiatric records for the patients. No psychiatric records for relatives were available and no structural interviews were conducted. 22 RNA was purified from 500 mg of tissue by Trizol reagent as described. 23 RNA integrity was evaluated by agarose gel electrophoresis and by measuring the 5 0 -to 3 0 -end ratio for GAPDH mRNA in the array data. Transcript profiling was carried out using Affymetrix HgU95A GeneChip oligonucleotide arrays (Affymetrix, Santa Clara, CA, USA). Each array contained 12 626 probe sets corresponding to full-length genes and clustered ESTs, which included 8100 distinct UniGene clusters. Sample labeling, hybridization and scanning were performed according to Affymetrix recommendations. Briefly, 10 mg of total RNA was incubated for 10 min at 701C with a HPLC-purified oligo (dT) primer containing a T7 RNA polymerase promoter site (GGCCAGTGAATTGTAATACGACT-CACTATAGGGAGGCGG(T) 24 (GENSET Inc., La Jolla, CA, USA). Following priming, cDNA was prepared using the SuperScript II cDNA synthesis kit (Invitrogen, Carlsbad, CA, USA) with the following conditions: 65 min at 501C for first-strand synthesis with Superscript II reverse transcriptase, followed by 150 min at 161C for second-strand synthesis with Escherichia coli ligase, E. coli polymerase and RNase H. cDNA was purified by phenol-chloroform extraction, followed by removal of the organic fraction using Phase Lock Gel I tubes (5 Prime to 3 Prime Inc., Boulder, CO, USA). Biotin-labeled cRNA was transcribed in an in vitro transcription reaction mixture containing T7 RNA polymerase, bio-11-CTP and bio-11-UTP (Enzo Laboratories, Farmingdale, NY, USA) for 16 h at 371C. The cRNA product was purified by RNeasy column, and quantitated by UV absorbance at 260 nm. In all, 15 mg of cRNA was fragmented for 35 min at 951C, then added to a 300 ml hybridization cocktail containing bovine serum albumin (0.5 mg/ ml) and herring sperm DNA (0.1 mg/ml; Promega, Madison, WI, USA) in 1 Â MES. Hybridization mixture (200 ml) was applied to an array and hybridization was allowed to proceed for 20 h at 451C on a rotisserie. Arrays were stained with streptavidinconjugated phycoerythrin (SAPE; Molecular Probes, Eugene, OR, USA). Fluorescence intensity was measured using the Affymetrix GeneChip laser scanner and reduced to relative expression values (average difference values) for each transcript using Affymetrix microarray suite version 4.0 software package (MAS4.0). Subsequent filtering of data and analyses used Microsoft Excel, Microsoft Access, SSPS 10.5, Splus statistical programs and other tools (see below). Updated versions of Affymetrix software became available (MAS5.0 and MAS5.1) after our statistical and functional analyses of the data generated using MAS4.0 were completed. Although these updated versions may have some advantages over MAS 4.0 in that they do not generate negative average difference values for low-abundance genes, this advantage has no significant effect on our analysis since such lowabundance genes are of low confidence and were specifically excluded from our analysis (see below). Given the fact that high-abundance genes are handled well by both MAS 4.0 and MAS 5.0/5.1, we consider MAS 4.0 to be suitable for analysis of the data presented here and re-examination of our data using MAS 5.1 not warranted.
Taqman s real-time reverse transcription-polymerase chain reaction (RT-PCR) was carried out as follows. Oligonucleotide primers and probes were designed according to Applied Biosystems recommendations using Primer Expresses software and were synthesized by Biosource International (Camarillo, CA, Gene expression in major depressive disorder C Aston et al [12] [13] [14] [15] [16] [17] [18] in 15.5 ml water were heated at 651C for 5 min. The mixture was iced for 2 min, then 3 ml of 10 Â RT buffer, 6 ml of 25 mM MgCl 2 , 3 ml of 0.1 M DTT was added and the mixture was heated at 421C for 2 min. A volume of 1.5 ml (75 U) Superscript II RT was added and incubated at 421C for 50 min. The reaction was terminated at 701C for 15 min, and then chilled on ice. RNase H (1 ml) was added, incubated at 371C for 20 min. Water was added to bring the final volume to 200 ml for subsequent plating.
cDNA (5 ml) was plated, in triplicate, in 96-well PCR plates (Applied Biosystems, Foster City, CA, USA). In all, 45 ml of reaction master mix containing 25 ml Platinum Quantitative PCR SuperMix-UDG (Cat. No. 11730-025; Invitrogen), 1 ml ROX reference dye (Part No. 12223-012; Invitrogen), 1 ml of 10 mM forward primer, 1 ml of 10 mM reverse primer, 1 ml of 10 mM probe and 16 ml of water was added. Controls containing no template were also plated. PCR reactions were carried out in the ABI PRISM 7700 Sequence Detection system (Applied Biosystems) using the following conditions: 501C for 2 min, 951C for 2 min, then 40 cycles of 951C, 15 s; 621C, 1 min. The fluorescence was detected and collected at each cycle. The threshold cycle (C T ) was determined for each probe set. A standard curve was generated by pooling total RNA from all the samples, and then performing cDNA synthesis. Five serial two-fold dilutions were plated in duplicate on the 96-well plate. The standard curve enabled C T values to be converted to RNA equivalents. RNA-equivalent values were averaged for the analysis. Data were normalized to GAPDH expression.
Data analysis
The samples were coded to blind the investigators who performed RNA purification and microarray analysis. The codes were broken after the arrays were scanned, 'average difference' (level of expression in MAS 4.0-based analysis) and 'absent/present' calls were generated for each gene and data were archived. To enable comparison of multiple microarray image files within a data set, the different analysis output files were normalized in MAS 4.0 by scaling to the same target intensity (1500), using all probe sets as recommended by Affymetrix. This normalization was chosen for the current study for the following reasons. First, this scaling may be performed blindly before the codes for the samples are broken and any quantitative data are collected. Second, it is independent of the subsequent comparison analysis. Third, this normalization effectively minimizes the influence of poorly detectable low-abundant transcripts. Instead, it favors the medium and highly abundant transcripts that are more reliably detected by microarrays, which were the major focus of the current study. Finally, there was near-linear relationship between expression values determined using this normalization from microarrays and from real-time RT-PCR ( Figure 1a ). The average correlation coefficient for all transcripts in repeated analyses of the same sample was greater than 0.99.
Microarray analysis for one control (c26) was repeated three times. Analyses of three other controls (c21, c23, c46), and one case with major depressive disorder (d20) were in duplicate. Mean values for repeated measurements of a sample were used for group comparisons. We defined candidate genes with changes in major depressive disorder as genes in which: (1) The average expression of the gene showed greater than 1.4-fold change compared with controls. (2) The difference was significant at Po0.05 using an unpaired Student's t-test (two-tailed). (3) Hybridization was sufficiently robust that the gene's expression was called 'present' by Affymetrix criteria in more than 20% of the samples. Differential expression of genes with o20% present calls between control and major depressive disorder groups was considered of low confidence in the current study. (4) The gene produced a mean average difference greater than 150 in at least one of the groups and no negative mean average difference values in any of the groups (since these genes represented low-level expression and were also considered of low confidence in the current study). The 1.4-fold change criterion was chosen based on magnitude of changes in gene expression observed in other postmortem brain studies, 4, [23] [24] [25] [26] [27] [28] and has been previously employed in a microarray study of prefrontal cortex in schizophrenia that used Affymetrix microarrays. 4 The rationale to use the 20% present call was to enable inclusion of genes that were called present predominantly in one of the subject groups. For example, suppose a gene is expressed in the depressed group (n ¼ 12) and displays a 50% present call in this group, but is not expressed in the control group (n ¼ 14) (present call 0%), than the overall present call will be 23% (greater than 20%).
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Functional grouping of genes was based on annotation from LocusLink, (http://www.ncbi.nlm.nih.gov/ LocusLink/), Online Mendelian Inheritance in Man (OMIM) (http://www.ncbi.nlm.nih.gov/omim/), Expression Analysis Systematic Explorer (EASE) (http://david.niaid.nih.gov/david/ease.htm), sequence homology analysis and literature searches. Statistical analysis was carried out using SSPS 10.5 and S-plus statistical programs. False Discovery Rate (FDR) 29 was calculated using BRB ArrayTools (http://linus.nci.-nih.gov/BRB-ArrayTools.html), with a confidence level of false discovery rate assessment of 95%). Analysis of gene categories significantly over-or under-represented among genes changed in patients with major depressive disorder was carried out based on Gene Ontology (GO) terms using Fisher's exact probability test and EASE computer program. 30 Bonferroni correction and global false discovery rate (10th percentile) were applied in order to control for multiple comparison effects.
Results
In our initial analysis, we considered all genes that were called present in at least one of the cases. Out of B12 000 transcripts assessed by the arrays, 7454 reached this criterion. Of these 7454 transcripts, 578 showed statistically significant difference (Po0.05) between patients with major depressive disorder and controls by unpaired two-sample ttest, while only approximately 300 genes should reach the P-level o0.05 by chance. Multivariate permutation tests using BRB ArrayTools showed that, when ordered by two-sample t-test P-value, the first 247 of 578 genes contained no more than 50 false discoveries (confidence level of false discovery rate assessment of 95%). Out of 578 genes, 469 were annotated with GO biological process terms. Statistical analysis, using EASE software, 30 was used to determine over-representation of these GO terms compared to the 5425 available GO terms for the whole array. This analysis revealed several biological functions significantly over-represented among genes changed in patients with major depressive disorder, compared to what would be expected by chance (Table 2) . Among these functions were cell communication, signal transduction, regulation of cell cycle and cytoskeletal organization (Table 2 ). Only the cell communication category remained marginally significant (P ¼ 0.05) when the Bonferroni correction was applied instead of global FDR. 1 Expression levels by RT-PCR are the threshold cycle (C T ) values converted to RNA equivalents and then normalized to GAPDH expression. 2 Expression levels by microarray are average difference values normalized to all genes present on the microarray by setting target sensitivity to 1500 to in order to normalize expression levels across all samples. Error bars are SEM Gene expression in major depressive disorder C Aston et al
In the subsequent analysis, in order to focus on the most robust changes, we applied additional and more stringent criteria for candidate changes. Specifically, in addition to statistical significance, we considered only genes that showed greater than 1.4-fold change, mean average difference greater than 150 in at least one of the groups, and called present in greater than 20% of all samples. In all, 225 genes satisfied these high stringency criteria (Table 3) . Of these 225 genes, 176 genes showed lower expression than in controls, while 49 showed greater expression that in controls (Table 3 ). Raw data for these genes are available from the authors by request.
Out of 225 genes, 185 were annotated with GO biological process terms. Over-representation analysis of these 185 genes, using EASE, revealed significant changes in gene categories related to neurogenesis and cell communication, as well as in four other GO terms (Table 4) . Within the neurogenesis GO term, there were several genes related to myelination (MOG, MOBP, PMP22, PLP1, KLK6, EP300) and axonal growth/synaptogenesis (KALIG1 and SEMAE). Since GO provides only overall functional categorization of genes, further more detailed analysis of gene changes was carried out using an intensive search of the literature for the 225 genes (Table 3 ).
This analysis revealed that expression of 17 genes related to myelination was decreased in patients with major depressive disorder. Eight of these 17 genes encode the structural components of myelin (CNP, MAG, MAL, MOG, MOBP, PMP22, PLLP, PLP1). Five other genes encode enzymes involved in the synthesis of myelin constituents (ASPA, UGT8), or are essential in regulation of myelin formation and metabolism (ENPP2, EDG2, TF, KLK6). OLIG2 is a transcription factor present exclusively in oligodendrocytes and oligodendrocyte precursors. SOX10 encodes a transcription factor regulating other myelination-related genes. Another gene, ERBB3, is involved in Schwann cell development. 31 Importantly, decreased expression of ERBB3 was independently revealed by two different probe sets targeted to two different regions of its mRNA (Table 3) . Three additional probe sets for ERBB3 also revealed decreased expression of this gene in major depressive disorder (fold change À4.7, P ¼ 0.0002, fold change À2.4, P ¼ 0.0051, and fold change À1.1, P ¼ 0.0033). One of these additional probe sets, however, had fold change less than À1.4 and two of the three produced 'present' calls less than 20% and were therefore not included in Table 3 . It is possible that different probe sets for ERBB3 reveal different splicing variants of ERBB3 transcripts. 32 Likewise, decreased expression of CNP, ENPP2 and PLLP were consistently shown by two independent probe sets for each of these three transcripts. Furthermore, altered expression of MAPT, PPP2R3, CDKN1C, HSPA2 and FOLH1 was each confirmed by consistent results from several independent probe sets targeted to different regions of their mRNAs (Table 3) , adding confidence to their identification.
Four genes involved in axonal growth/guidance (SEMAE, TAX1, Kal1 and MAPT) display altered expression in patients with major depressive disorder. In major depressive disorder there was also decreased expression of genes encoding synaptic proteins synaptogyrin 2, synaptojanin 2, NAPA and VAMP3, as well as increased expression of DLGAP1 and catenin (cadherin-associated protein) a-like 1. DLGAP1 protein interacts and co-localizes with NMDAR2, APC and b-catenin, which, in turn, is associated with cadherins. 33 The expression of the cadherin 19 gene was decreased in patients with major depressive disorder.
Gene expression for nine protein kinases, four protein phosphatases and seven other proteins related to phospho-regulated signal transduction was decreased in major depressive disorder. Expression of the serotonin 5-HT4A receptor, protein kinase C theta 
a Gene categories were defined using EASE program within biological process categorization in GO.
Gene expression in major depressive disorder C Aston et al a Genes selected using 'high-stringency criteria', specifically: (1) Po0.05, (2) greater than 1.4-fold change, (3) mean average difference greater than 150 in at least one of the groups and (4) called present in greater than 20% of all samples (partial list, complete list of genes is available in supplemental materials). P-values are from the Student's t-test (two-tailed), calculated using arithmetic mean. % present call is the percentage of samples with a present call for that gene (calculated for combined control and major depressive disorder groups). Data from two independent probe sets producing present call 420% for each of the ERBB3, CNP, PLLP, ENPP2, MAPT, PPP2R3, CDKN1C, HSPA2, and FOLH1 genes are shown.
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(PRKCQ) and phosphoinositide-3-kinase (PIK3R1) was downregulated, providing some support for the role of serotonergic systems in depression. There was also decreased expression of the GABRB2 receptor gene, as well as of an endothelin type B-like receptor, GPR37, abundantly expressed in the human brain. A number of other genes involved in signal transduction demonstrated altered expression in patients with major depressive disorder (Table 3) .
In all, 13 genes involved in regulation of chromatin and gene expression, and four genes involved in cell cycle regulation, displayed altered expression in patients with major depressive disorder (Table 3) . Among these genes were RNASE1, CEP2 and DICER1, a ribonuclease gene which produces small RNAs that repress gene expression.
Importantly, major functions that were identified by a search of the literature fell within GO terms associated with genes significantly over-represented that were changed in major depressive disorder, as determined by EASE. These included neurogenesis, signal transduction, cell communication and regulation of cell cycle (see above). Direct statistical analysis of over-representation of our gene categories, defined by an intensive search of the literature, was unfeasible because these terms are not incorporated in EASE, while categorization of more than 6000 genes by intensive literature search, which is necessary for such an analysis, is impractical. Nevertheless, we attempted to evaluate the degree of over-representation for the group of genes related to myelination. To this end, we searched GO biological process annotations, gene names and other gene annotations using key words 'myelin', 'oligodendrocyte', 'oligodendroglia' and 'glia'. The proportion of myelination-related genes identified by this search in the total list of expressed genes was 28 out of B6000. In contrast, a significantly greater proportion, specifically seven out of 225, was identified by this search in our list of candidate genes. Note that not all of the 17 myelination-related genes were revealed by searching for key words in the annotations. This highlights the current larger issue of incomplete annotation of microarray genes.
When an additional analysis using more stringent criteria (genes called present in greater than 50% of all samples) was carried out, similar conclusions were reached. We found that greater than 80% of genes reported in our manuscript are above the 50% present call criteria in both diagnostic groups, and none of the genes with present call less than 50% are essential for the conclusions reached in the manuscript.
Confirmation by Taqman
s real-time RT-PCR The expression of four genes was measured in the same tissue samples using quantitative Taqman s realtime RT-PCR in order to confirm altered expression revealed by microarrays. Genes selected for confirmation represented promising candidate mechanisms for major depressive disorder. MAG and PLLP are members of the myelination-related group. RNASE1 represents a group of genes associated with regulation of gene expression. GRP37 is a novel endothelin type B-like receptor abundantly expressed in neuronal cells. 34 The house-keeping gene, GAPDH, was measured in the same samples and used to normalize measurements of four other genes. The measurements by RT-PCR were highly correlated with measurements by microarrays (Figure 1 ), confirming significant decreases in MAG (P ¼ 0.001, fold change ¼ À5.0),
and GPR37 (P ¼ 0.015, fold change ¼ À2.19).
Seven patients with major depressive disorder were receiving CNS drugs at time near to death (Table 1) , which could potentially lead to a bias in identifying candidate changes. Therefore, an additional analysis was performed, which was limited to a subgroup of five patients who were not receiving CNS medication at time near death or had probably never been treated. The direction of change was confirmed for all 225 genes (Table 3) ; however, fold change was not always of the same magnitude as in the total group of patients. Although long-lasting effects of medication Gene expression in major depressive disorder C Aston et al cannot be ruled out, these data are consistent with the idea that the majority of the changes were unlikely due to acute medication. The direction of change was also confirmed for these 225 genes when the analysis was limited to a subgroup of patients (n ¼ 7) who were not victims of suicide, arguing against a bias associated with suicide ( Table 3 ). The diagnostic groups were closely balanced in age, gender, PMI, brain pH and overall RNA quality (Table 1) . Thus, the findings here were unlikely influenced by these demographics. Additionally, no genes that were previously reported to be age-or gender-dependent [35] [36] [37] were present in our list. Only two controls and four subjects with major depressive disorder had a history of substance abuse, and three of these cases were abstinent for several years prior to death, arguing against a significant effect of substance abuse on our findings. Furthermore, additional analysis excluding cases with a history of substance abuse confirmed all changes found in the total groups of subjects, providing further evidence that these changes were not due to substance abuse (see supplemental materials). The potential effect of brain pH is of particular importance. 38, 39 A recent microarray study revealed that the lower pH samples exhibited a decrease in transcripts involved in energy metabolism and proteolytic activities, and a consistent increase of transcripts for stress-response proteins and transcription factors. 39 These pH/agonal state-associated changes are not among those we found to be the most consistent changes in patients with major depressive disorder, such as changes in myelination-and synaptic function-related genes. Nevertheless, we performed additional analysis using cases that all died of cardiac events only (nine controls and six patients with major depressive disorder) and who therefore were likely to have experienced similar agonal states. Analysis of these smaller groups of cases confirmed changes found in total groups of cases (see supplemental materials), providing further evidence that changes are disease related, rather than brain pH/agonal state-associated. In addition, our groups were well matched in overall indexes of mRNA quality influenced by brain pH (Table 1) .
Discussion
Transcriptional profiling revealed significant expression changes in families of genes involved in neurodevelopment, signal transduction, cell communication and myelination. There was decreased expression of 17 genes related to oligodendroglia in the temporal cortex from subjects with major depressive disorder compared with normal controls. Most of these genes, that is, MAG, MAL, MOG, MOBP, PMP22, PLLP, PLP1, CNP, encode structural components of myelin. Other genes encode enzymes synthesizing myelin components (ASPA, UGT8), regulate myelin formation or maintenance (ENPP2, EDG2, TF, KLK6), control growth of myelin-producing cells (ERBB3, ENPP2) or regulate transcription of genes involved in myelination (SOX10). Several of these genes cause myelination-related disorders affecting brain function in mice and humans. For example, PLP1 is responsible for X-linked demyelination disorder in mice, and for Pelizaeus-Merzbacher disease in humans. 40 Pelizaeus-Merzbacher disease is associated with mental deficiency. 41 ASPA encodes aspartoacylase, which catalyzes the hydrolysis of N-acetyl L-aspartic acid, a process that helps maintain white matter. Defects in aspartoacylase cause Canavan disease which is characterized by loss of the axon's myelin sheath, spongy degeneration of the white matter and, among other features, may manifest severe mental defects.
42
SOX10 encodes a transcription factor regulating myelination-related genes.
43 SOX10 is associated with deficiency of myelination in Waardenburg-Shah syndrome 43 and causes loss of glia and neurons in Dom mice. 43 Among other genes, SOX10 regulates connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease. 44 During late stages of embryogenesis, the expression of SOX10 is confined to glial cells. 45 In the central nervous system, SOX10 expression occurs later but progressively increases to reach maximal levels during adulthood, being mainly confined to glia of the oligodendrocyte type. 44 The SOX proteins belong to the HMG box superfamily of DNA-binding proteins. These factors play key roles in decisions of cell fate during diverse developmental processes, and display properties of both classical transcription factors and architectural components of chromatin. 46 CNP encodes 2 0 ,3 0 -cyclic nucleotide 3 0 -phosphodiesterase, which plays a role in signaling pathways mediated by lipid-protein domains, 47 and is a commonly used marker of myelin. 48 ENPP2 encodes an ectonucleotide pyrophosphatase/phosphodiesterase 2 that may play a role during active myelination and/or late stages of oligodendrocyte differentiation, possibly through cell-cell and/or cell-extracellular matrix recognition. 49 EDG2 encodes a G-proteincoupled receptor involved in myelin formation or maintenance.
50 UGT8 encodes cerebroside synthetase, an enzyme involved in synthesis of galactocerebrosides, which are abundant sphingolipids of the myelin membrane. 51 ERBB3 encodes a member of the ErbB family of protein tyrosine kinases which are involved in myelination through the control of growth and development of Schwann cells, specialized cells that wrap around nerve axons to provide electrical insulation. 52 OLIG2 is a transcription factor involved in control of oligodendrocyte differentiation. 53 These consistent decreases in multiple myelination-related genes indicate a disruption in myelination/oligodendrocyte function in major depressive disorder and may provide the molecular basis for changes in white matter revealed by neuroimaging and structural studies. [54] [55] [56] [57] [58] In parallel with findings here, significant reduction in density of oligodendrocytes was reported in Brodmann area 9 59 and amygdala 60 from patients with major depressive disorder.
Gene expression in major depressive disorder C Aston et al In addition to deficient electrical insulation of nerve axons, abnormal myelination/oligodendrocyte function may cause synaptic degeneration. 61 Deficient expression of myelination-related genes could therefore be a part of more general abnormalities in neuronal networking, which include synaptic function. Altered expression of genes that guide axonal growth (SEMAE, TAX1, MAPT and KAL1) indicates abnormal axonal growth and synaptogenesis, while decreased expression of synaptic protein genes (SYNJ2, SYNGR2, VAMP3, NAPA and RALA) could indicate decreased synaptic function in major depressive disorder. Abnormal expression of a synapse regulator DLGAP1, which is associated with NMDA receptors, could further impair synaptic function in major depressive disorder.
The data from the current study indicate that, in addition to abnormalities related to myelination/ synaptogenesis, nerve cell communication in major depressive disorder may be altered due to functional changes in multiple components of signal transduction mechanisms. Significant numbers of signal transduction genes displayed altered expression in patients with major depressive disorder (Tables 2-4). Of interest also was decreased expression of FOLH1, a gamma-glutamyl carboxypeptidase, which is involved in regulation of excitatory signaling in the brain. 62 Its altered activity has been associated with various human neurological disorders including schizophrenia, 63 Alzheimer's disease and Huntington's disease. 64 Decreased expression of oligodendroglia-related genes ERBB3, MAG, MAL, TF and CNP has previously been reported in prefrontal cortex of chronic elderly schizophrenics. 4 More recently, decreased expression of ERBB3, MAG and five other oligodendrocyterelated genes, that is, MOG, MOBP, OLIG2, SOX10 and PLP1 was reported in prefrontal cortex from another group of patients with schizophrenia, as well as in patients with bipolar disorder. 10 Decreased expression of PLP1 was reported in yet another group of patients with schizophrenia. 8 Besides these genes, expression of four other genes (HSPA2, GRP37, FOLH1, RNase A) was changed in both patients with major depressive disorder examined here and in elderly patients with chronic schizophrenia. 4 It is possible that major depressive disorder, bipolar disorder and schizophrenia may share some common molecular abnormalities, particularly those related to oligodendroglial function. Changes in some myelination-related genes were also reported in the frontal and motor cortices of alcoholics. 65, 66 There is a high rate of comorbidity of alcoholism and other psychiatric disorders, including schizophrenia and mood disorders. 67, 68 Interestingly, no changes in myelination-related genes were found in the temporal cortex of patients with alcohol use disorders in a microarray study that was specifically designed to reduce effects of comorbidity and traits shared between alcohol use disorders and other psychiatric disorders. 12 Thus, the specificity of changes in myelination-related genes with respect to different psychiatric disorders remains to be investigated.
The majority of patients with major depressive disorder studied here were treated with psychotropic drugs. Therefore, it is important to note that changes in gene expression were confirmed in a subgroup of patients who had no history of drug treatment or were free of drugs at time near death. It is also noteworthy that similar changes in myelination-related and some other genes have been previously reported in patients with schizophrenia 4 or bipolar disorder 10 who were free of psychotropic drugs, or were treated with drugs that were different from those used in cases with major depressive disorder studied here. Importantly, a recent microarray study in rats revealed no evidence for antidepressant-induced changes in myelinationrelated and other genes reported in the current study. 69 Similarly, no changes in myelination-related genes in association with antidepressant treatment were found using microarrays in human brain. 36 Although taken together, these observations are inconsistent with the idea that the majority of changes reported here are drug effects, additional future studies of larger groups of drug free patients as well as animal studies are necessary to clarify this issue.
To summarize, transcriptional profiling revealed evidence of changes in cell communication and signal transduction systems that might contribute to oligodendroglial and synaptic abnormalities in the temporal cortex from patients with major depressive disorder. Further studies are necessary to confirm these findings and to determine whether these and other changes in gene expression are present in other brain regions implicated in major depressive disorder, particularly in the prefrontal cortex and amygdala.
